ProCE Banner Activity

CLL: Treatment Decisions Driven by del(17p)/TP53 Mutation

Slideset Download
In this downloadable slideset, Andrew D. Zelenetz, MD, PhD, examines and discusses the use of del(17p)/TP53 mutations to guide treatment of patients with chronic lymphocytic leukemia.

Released: June 05, 2018

Expiration: June 04, 2019

No longer available for credit.

Share

Faculty

Andrew D. Zelenetz

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Agios Pharmaceuticals

Bayer Healthcare Pharma

Celgene TEXT Only

Foundation Medicine

Loxo Oncology

Merck Oncology

Faculty Disclosure

Primary Author

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York